Avacta Therapeutics Showcases Next Generation of pre|CISION® Medicines at R&D Spotlight Event

October 30, 2024 09:26 PM AEDT | By Team Kalkine Media

Google News:

Avacta Therapeutics Showcases Next Generation of pre|CISION® Medicines at R&D Spotlight Event — Image source: Shutterstock

Recent News

EUR/USD poised to rack up more gains as ECB and Fed rate paths set to...

Carney launches ‘One Canadian Economy’ Act to unify trade, approvals

Trump signs orders to enhance drone defenses, support supersonic trave...

US job growth in May tops forecasts, but Macquarie warns cracks are em...

Highlights

Avacta Therapeutics hosted a live R&D Spotlight event in London, focusing on its next-generation peptide drug conjugates (PDC) aimed at targeted tumor treatment.

The company presented details about its innovative pre|CISION® candidates and ongoing pipeline programs, including AVA6000, AVA6103, and AVA7100.

Avacta emphasized its strategic focus on breast cancer therapies and outlined near-term milestones for its programs.

Avacta Therapeutics (LSE:AVCT), a pioneering life sciences company, is hosting a live R&D Spotlight event titled "Next Generation of pre|CISION® Medicines" in London today. The event showcases Avacta's advanced developments in peptide drug conjugates (PDCs) designed to deliver potent antitumor payloads directly to tumors, enhancing treatment efficacy while minimizing damage to surrounding healthy tissues.

The company’s proprietary technology enables the targeted delivery of cytotoxic drugs within the tumor microenvironment (TME), providing a promising avenue for cancer treatment. During the event, Avacta will present its next-generation follow-on candidates, highlighting their unique features and the specific patient populations they aim to serve.

Key developments in Avacta's pipeline include novel pre|CISION® candidates that were recently discussed at the EORTC-NCI-AACR Triple Meeting held in Barcelona. These presentations provided insights into the properties of the new candidates and the patient demographics they target.

Avacta's pipeline is marked by its differentiation, particularly through its AVA6000, AVA6103, and AVA7100 programs, which address substantial market needs in oncology. Each program has been strategically developed to meet the challenges faced in cancer treatment, and the company will elaborate on the near-term milestones expected for these innovative assets during the event.

A significant focus of the event will be Avacta’s strategic initiatives within the breast cancer treatment landscape. The company aims to solidify its presence in this indication, discussing how its therapies will advance in this area and contribute to improved patient outcomes.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.